Elevated adenosine monophosphate deaminase activity in Alzheimer's disease brain.
Level 4 - case-series / case-control
Postmortem case-control study using human brain tissue
PubMed 9880040 · doi:10.1016/s0197-4580(98)00083-9
What was done
The authors measured adenosine monophosphate (AMP) deaminase enzyme activity, protein expression, and mRNA levels in postmortem brain tissue from individuals with Alzheimer's disease and age-matched controls across three brain regions: the cerebellum, occipital cortex, and temporal cortex.
What was found
Compared to controls, Alzheimer's disease brain tissue exhibited a 1.6- to 2.4-fold increase in AMP deaminase activity in the cerebellum, occipital cortex, and temporal cortex, with similar increases observed in protein and mRNA levels. Absolute baseline values, donor counts, and variance or significance metrics were not reported in the abstract.
Why it matters
Elevated AMP deaminase activity provides a potential biochemical explanation for increased ammonia production implicated in Alzheimer's disease pathogenesis.
Limits
The abstract does not disclose sample sizes, postmortem intervals, or donor clinical details. Direct brain ammonia levels were not measured, and postmortem tissue analysis cannot determine whether elevated enzyme activity is a primary driver or a downstream consequence of neurodegeneration.
Cited by
- supports The enzyme AMP deaminase is elevated in the brains of patients with Alzheimer's disease.